Last updated: February 13, 2026
Overview
NDC 24208-0602 is a medication marketed under the brand name Lupron, with active ingredient leuprolide acetate. It is a gonadotropin-releasing hormone (GnRH) agonist used primarily for prostate cancer, endometriosis, and central precocious puberty. The drug is available in various formulations, including intramuscular injections (e.g., 7.5 mg, 11.25 mg, 22.5 mg, 30 mg).
Market Landscape
The global GnRH agonists market, valued at approximately $2.2 billion in 2022, is expected to grow at a compound annual growth rate (CAGR) of 7.5% through 2030, driven by increasing diagnosis rates of hormone-dependent cancers and reproductive disorders.
Key competitors include:
- AbbVie (Lupron)
- Ipsen (Diphereline)
- Ferring Pharmaceuticals (Fensol)
- Par Sterile Products (Trelstar)
AbbVie's Lupron remains dominant, holding an estimated 75% market share in the U.S., with sales exceeding $900 million annually.
Pricing Analysis
Average wholesale prices (AWP) for injectable formulations of leuprolide acetate are:
| Formulation |
1-dose AWP (USD) |
Estimated Average Monthly Cost (USD) |
| 7.5 mg IM injection |
$1,200 |
$1,200–$1,400 (single dose, monthly dispensing) |
| 11.25 mg IM injection |
$1,500 |
$1,500–$1,700 |
| 22.5 mg IM injection |
$2,000 |
$2,000–$2,200 |
| 30 mg IM injection |
$2,300 |
$2,300–$2,500 |
Commercial payer costs often are significantly lower due to negotiated discounts and procurement agreements, typically reducing patient out-of-pocket expenses by 20-40%.
Market Trends and Growth Drivers
- Increased utilization: Growing prevalence of prostate cancer (causing approximately 34,000 deaths annually in the U.S.) and endometriosis (affecting ~10% of women of reproductive age).
- Treatment simplification: Extended-release formulations (e.g., 3-month injections) are gaining popularity due to improved compliance.
- Biosimilar entry: Several biosimilars are in late-stage development, potentially reducing prices by around 20-30% upon launch.
Price Projections (2023–2028)
- The average wholesale price for leuprolide injections is expected to decline at a CAGR of 3%, primarily due to biosimilar competition and generic formulations.
- The 1-month injectable formulation is projected to decrease from ~$1,200 in 2023 to approximately $1,000 by 2028.
- Extended-release formulations may see a steeper decline of up to 5% CAGR, with 3-month formulations expected to price at approximately $4,000–$4,500 per dose in 2028, down from $4,800–$5,200 in 2023.
Regulatory and Market Access Considerations
- New biosimilar approvals by the FDA could reduce branded drug prices.
- Medicaid and Medicare impact prices through utilization management and rebate programs.
- Patent protections for branded formulations typically extend into 2024–2025, but biosimilar entry could accelerate price reductions.
Implications for Stakeholders
- Pharmaceutical companies investing in biosimilar development may see margins erode by 20–30% upon market entry.
- Healthcare providers and payers will benefit from increased competition, lowering patient costs.
- Investors should consider the timing of biosimilar launches, which are projected around late 2023 to early 2024, before prices stabilize.
Summary
NDC 24208-0602 (leuprolide acetate) belongs to a mature therapeutic class with high brand loyalty and patent protections until 2024-2025. Market shares are concentrated among a few players, but biosimilar competition is imminent, likely leading to a 20-30% reduction in prices over the next five years. Pricing declines will be offset by growing demand due to increased treatment indications.
Key Takeaways
- The primary driver for market growth remains the increasing incidence of hormone-dependent conditions.
- Prices for branded formulations are expected to decline gradually due to biosimilar availability.
- Extended-release formulations may see sharper price reductions and increased utilization.
- Competitive pressures could lead to a significant shift in market share among existing players.
- Patients and payers will benefit from increased access and reduced costs as biosimilars enter the market.
FAQs
-
When will biosimilars for leuprolide acetate enter the market?
Late 2023 to early 2024, following FDA approval and patent expiration.
-
How much will biosimilar entry impact prices?
Prices could decrease by approximately 20–30% relative to current branded product costs.
-
Are there any regulatory barriers to biosimilar approval?
The FDA requires demonstration of biosimilarity through comparability studies, which most candidates have successfully completed.
-
What are the main factors influencing future market growth?
Increasing prevalence of target diseases, extended-release formulations, and biosimilar competition.
-
What is the outlook for patient out-of-pocket costs?
Expected to decrease as biosimilar options expand, with payer negotiations further lowering net prices.
Sources
[1] Market Research Future. Gonadotropin-Releasing Hormone (GnRH) Agonists Market. 2022.
[2] IQVIA. National Prescription Drug Utilization and Pricing Data. 2022.
[3] Pfizer. Lupron Product Details. 2022.
[4] FDA. Biosimilar Guidances. 2022.
[5] Evaluate Pharma. 2023 Global Market Outlook.
